AKT1 and cancer: Overactivation of the phosphatidylinositol 3 kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK) pathways is a well-known trait in cancer, and compounds or modalities that suppress these signaling pathways represent an attractive approach to strengthening the effectiveness of regorafenib.